Saudi investment firm Hevolution invested $20 million in US firm

Hevolution Foundation, a Saudi investment firm focused on aging science, has invested $20 million in Aeovian, a San Francisco based biopharmaceutical company.

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted small molecules to restore cellular metabolic quality control. Hevolution has also invested in Rubedo Life Sciences $40 million Series A round. (Hevolution is a Saudi investment firm focused on aging science with an annual budget of up to $1 billion. They also invest in platforms and technologies that aim to compress drug development timelines or increase accessibility to therapeutics.)

Hevolution is listed in the Middle East Investors Directory with the code AJ49.